(Q38335718)

2 September 2017

1 reference

title

Infection risk associated with anti-TNF-α agents: a review (English)

1 reference

2 September 2017

0 references

0 references

Giuseppe Murdaca

1

1 reference

2 September 2017

Francesca Spanò

2

1 reference

2 September 2017

Miriam Contatore

3

1 reference

2 September 2017

Andrea Guastalla

4

1 reference

2 September 2017

Elena Penza

5

1 reference

2 September 2017

Ottavia Magnani

6

1 reference

2 September 2017

Francesco Puppo

7

1 reference

2 September 2017

language of work or name

English

0 references

publication date

29 January 2015

1 reference

Expert Opinion on Drug Safety

2 September 2017

published in

1 reference

2 September 2017

volume

14

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

571-582

1 reference

Antibody therapy for rheumatoid arthritis

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Emerging biologic drugs for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Potential use of TNF-α inhibitors in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Efficacy and safety of etanercept in chronic immune-mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Biologic therapies in psoriasis: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Guideline for anti-TNF-alpha therapy in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Vascular effects of biologic agents in RA and spondyloarthropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Endothelial dysfunction in rheumatic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Recurrence of active tuberculosis following resumption of anti-TNF-α therapy in a patient with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Listeria meningitis associated with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Listeria infection in patients on anti-TNF treatment: report of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Does administration of infliximab increase susceptibility to listeriosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Sepsis caused by Listeria monocytogenes related with the use of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

[Listeria meningitis in a patient with Crohn's disease--a seldom, but clinically relevant adverse event of therapy with infliximab]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Glück et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Listeriosis in patients receiving biologic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

High incidence of Listeria monocytogenes in European red smear cheese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Pneumocystis carinii pneumonia in patients without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

21 January 2018

Pneumocystis pneumonia

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Pneumocystis pneumonia developed in two patients with rheumatoid arthritis during treatment of adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Adalimumab safety in global clinical trials of patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Acute pulmonary histoplasmosis in a patient with uveitis after infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

TNF-alpha antagonism generates a population of antigen-specific CD4+CD25+ T cells that inhibit protective immunity in murine histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Hepatitis B virus DNA contains a glucocorticoid-responsive element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Ten year follow-up of healthy children who received one or two injections of varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1009036

10.1517/14740338.2015.1009036

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference